Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Live Q&A: Managing HCV: Tackling Tough Cases

Premiere Date: Thursday, July 21, 2022

This activity offers CE credit for:

1. Medicine (accme)
2. Nursing (ANCC)
3. Pharmacy (acpe)
4. PA (aapa)
5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, July 21, 2023
Note: Credit Is No Longer Available

Faculty

Nancy Reau, MD (Moderator) Professor of Medicine Richard B. Capps Chair of Hepatology Chief, Section of Hepatology Associate Director, Solid Organ Transplantation Rush University Medical Center Chicago, IL

Paul Y. Kwo, MD  Professor of Medicine Director of Hepatology Stanford University School of Medicine Stanford, CA

Anthony Martinez, MD, AAHIVS, FAASLD  Associate Professor of Medicine Jacobs School of Medicine University at Buffalo Medical Director, Hepatology Erie County Medical Center Buffalo, NY

Statement of Need

The low rates of hepatitis C virus (HCV) screening in real-world practice indicate the existence of barriers that need to be overcome. In addition to the COVID-19 pandemic causing delays and/or discontinuations in many hepatitis elimination efforts, there are barriers on the provider level, such as communication challenges, low awareness of HCV, and poor knowledge of HCV screening recommendations. Patient-level barriers include lack of knowledge and awareness of HCV infection, confusion about transmission, and lack of insurance to pay for screening. It is essential that clinicians who treat patients with HCV are aware of these barriers and are equipped with strategies to overcome them in order to ensure screening and optimal management of all populations at risk for HCV infection.

This live Q&A session is your opportunity to ask questions based on the CME Outfitters BriefCase series covering the latest guideline recommendations and evidence supporting optimal management of complex HCV cases.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Implement CDC screening guidelines in practice to improve the detection and diagnosis of HCV.
• Apply efficacy and safety data to treatment decisions for optimal management of HCV.
• Integrate routine surveillance for HCC into clinical follow-up for patients with HCV.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

U.S. and international physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in primary care

Credit Information

EACCME:
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Reau reports the following financial relationships:

Consultant: AbbVie Inc.; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; and Merck & Co.

Grants/Research Support: GENFIT; Intercept Pharmaceuticals, Inc.; and Shire

Dr. Kwo reports the following financial relationships:

Advisory Board: AbbVie Inc.; Aligos Therapeutics Inc.; Ambys Medicines; Antios Therapeutics, Inc.; CVS; Eisai Inc.; Enanta Pharmaceuticals, Inc.; Gilead Sciences, Inc.; HepQuant; Mallinckrodt Pharmaceuticals; and Surrozen

Consultant: Drug Farm; Durect Corporation; Generon; Inventiva; Mirum Pharmaceuticals; and Syneos Health

Dr. Martinez reports the following financial relationships:

Advisory Board: Antios Therapeutics, Inc.; Eisai Inc.; and Intercept Pharmaceuticals, Inc.

Consultant: Antios Therapeutics, Inc.; Eisai Inc.; and Intercept Pharmaceuticals, Inc.

Dr. Ramers reports the following financial relationships:

Advisory Board: AbbVie Inc. and Gilead Sciences, Inc.

Consultant: AbbVie Inc.; Gilead Sciences, Inc.; and ViiV Healthcare

Grants (Institutional Support): Gilead Sciences, Inc.

Grants (Programmatic Support): AbbVie Inc. and Gilead Sciences, Inc.

Speakers Bureau: AbbVie Inc.; Gilead Sciences, Inc.; and ViiV Healthcare

The following peer reviewers and CME Outfitters staff have no financial relationships to disclose:

Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)

Susan Perry (planning committee)

Kellie Busby, PharmD (planning committee)

Janan Sawar, PharmD (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).